IGM Biosciences (IGMS)
(Real Time Quote from BATS)
$8.31 USD
+0.22 (2.72%)
Updated Jun 5, 2024 01:18 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IGMS 8.31 +0.22(2.72%)
Will IGMS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for IGMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IGMS
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
IGMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for IGMS
IGM Biosciences to Present at the Jefferies Healthcare Conference
Biotech Alert: Searches spiking for these stocks today
In-Depth Examination Of 6 Analyst Recommendations For IGM Biosciences
Maintaining Hold on IGM Biosciences: Assessing Acquisition Impact and Awaiting Clinical Data
Analysts’ Top Healthcare Picks: Silk Road Medical (SILK), Eli Lilly & Co (LLY)